These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis. Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144 [TBL] [Abstract][Full Text] [Related]
3. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829 [TBL] [Abstract][Full Text] [Related]
4. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis. Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895 [TBL] [Abstract][Full Text] [Related]
5. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis. Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152 [TBL] [Abstract][Full Text] [Related]
16. Toll-like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor β-Dependent Fibroblast Activation. Fang F; Marangoni RG; Zhou X; Yang Y; Ye B; Shangguang A; Qin W; Wang W; Bhattacharyya S; Wei J; Tourtellotte WG; Varga J Arthritis Rheumatol; 2016 Aug; 68(8):1989-2002. PubMed ID: 26946325 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis. Yamamoto A; Saito T; Hosoya T; Kawahata K; Asano Y; Sato S; Mizoguchi F; Yasuda S; Kohsaka H Arthritis Rheumatol; 2022 May; 74(5):860-870. PubMed ID: 34882985 [TBL] [Abstract][Full Text] [Related]
18. A Human Skin Model Recapitulates Systemic Sclerosis Dermal Fibrosis and Identifies COL22A1 as a TGFβ Early Response Gene that Mediates Fibroblast to Myofibroblast Transition. Watanabe T; Baker Frost DA; Mlakar L; Heywood J; da Silveira WA; Hardiman G; Feghali-Bostwick C Genes (Basel); 2019 Jan; 10(2):. PubMed ID: 30678304 [No Abstract] [Full Text] [Related]
19. Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis. Pashaei M; Farhadi E; Kavosi H; Madreseh E; Enayati S; Mahmoudi M; Amirzargar A Inflammopharmacology; 2024 Oct; 32(5):3181-3193. PubMed ID: 39167314 [TBL] [Abstract][Full Text] [Related]
20. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis. Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]